Review Article
Gene Expression Profiling for In Silico Microdissection of Hodgkin's Lymphoma Microenvironment and Identification of Prognostic Features
Table 1
Gene expression profiling studies of nonmicrodissected cHL and survival.
| | Reference | cHL tumor samples | Microarray platform N° of genes | Control samples | Gene signature associated with | Validation set | Multivariate analysis |
| | [29] | 21 samples limited and advanced stages | Home-made genes | Cell lines (RS and non RS) tissues (adenitis, lymphomas) | Sustained complete remission | No | No | | [30] | 29 samples advanced stages | Home-made (CNIO) genes | Cell lines (RS and non RS) tissues (adenitis) | Sustained complete remission | 250 samples IHC TMA | No | | [28] | 63 samples limited and advanced stages | Affymetrix Oligonucleotide genes | Cell lines (RS and non RS) tissues (adenitis, lymphomas) | Sustained complete remission | 146 samples IHC TMA | EFS OS | | [31] | 130 samples limited and advanced stages | Affymetrix Oligonucleotide genes | No | Absence of progression or relapse | 166 samples IHC TMA | PFS DSS |
|
|
cHL: classical Hodgkin lymphoma; RS: Reed Sternberg; IHC: immunohistochemistry; TMA: tissue microarray; EFS: event-free survival; OS: overall survival; PFS: progression-free survival; DSS: disease-specific survival.
|
